Oppenheimer Holdings, Inc. Reaffirms Buy Rating for Trevena, Inc. (TRVN)

Oppenheimer Holdings, Inc. restated their buy rating on shares of Trevena, Inc. (NASDAQ:TRVN) in a research note issued to investors on Monday. Oppenheimer Holdings, Inc. currently has a $5.00 price target on the biopharmaceutical company’s stock. Oppenheimer Holdings also issued estimates for Trevena’s Q1 2018 earnings at ($0.18) EPS, Q2 2018 earnings at ($0.17) EPS, Q3 2018 earnings at ($0.21) EPS and Q4 2018 earnings at ($0.26) EPS.

Other analysts have also recently issued research reports about the stock. Cowen and Company restated a buy rating and set a $10.00 target price on shares of Trevena in a research note on Friday, August 4th. HC Wainwright cut their target price on shares of Trevena from $8.00 to $7.00 and set a buy rating for the company in a research note on Thursday, October 12th. Barclays PLC cut shares of Trevena from an overweight rating to an equal weight rating and cut their target price for the stock from $15.00 to $2.50 in a research note on Monday, October 16th. Needham & Company LLC cut their target price on shares of Trevena from $9.00 to $7.00 and set a buy rating for the company in a research note on Wednesday, November 8th. Finally, Zacks Investment Research cut shares of Trevena from a hold rating to a sell rating in a research note on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. Trevena presently has a consensus rating of Buy and a consensus target price of $8.75.



Shares of Trevena (TRVN) opened at $1.49 on Monday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.92 and a current ratio of 4.92. Trevena has a 12 month low of $1.35 and a 12 month high of $8.00.

Trevena (NASDAQ:TRVN) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.06. During the same quarter last year, the firm posted ($0.57) EPS. research analysts forecast that Trevena will post -1.29 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/16/oppenheimer-holdings-inc-reaffirms-buy-rating-for-trevena-inc-trvn.html.

A number of large investors have recently added to or reduced their stakes in TRVN. American International Group Inc. increased its position in Trevena by 7.1% during the first quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 1,816 shares during the period. Nationwide Fund Advisors increased its position in Trevena by 92.1% during the second quarter. Nationwide Fund Advisors now owns 49,132 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 23,557 shares during the period. Bourgeon Capital Management LLC increased its position in Trevena by 56.8% during the second quarter. Bourgeon Capital Management LLC now owns 53,031 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 19,200 shares during the period. Alliancebernstein L.P. increased its position in Trevena by 51.9% during the second quarter. Alliancebernstein L.P. now owns 55,300 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 18,900 shares during the period. Finally, Virtu KCG Holdings LLC increased its position in Trevena by 144.0% during the second quarter. Virtu KCG Holdings LLC now owns 58,660 shares of the biopharmaceutical company’s stock worth $135,000 after acquiring an additional 34,618 shares during the period. 57.71% of the stock is currently owned by institutional investors and hedge funds.

About Trevena

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply